Between Two Ventricles

A Call to ACTION

Dr. Phil Adamson interviews Angela Lorts, MD, MBA May 5, 2021

In this episode, Dr. Angela Lorts, Co-Executive Director of the ACTION Learning Network (Advanced Cardiac Therapies Improving Outcomes Network) and Director of the Ventricular Assist Device Program at Cincinnati Children’s Hospital Medical Center will discuss the importance of using a collaborative methodology with quality improvement methods to improve outcomes and define best practices. Dr. Lorts will also share how ACTION has been instrumental to the pediatric heart failure and congenital heart disease patient population.

COVID-19 and ECMO Therapy: Reflections One Year Into A Global Pandemic

Dr. Phil Adamson interviews Daniel Goldstein, M.D.
April 29, 2021

In this episode, Dr. Goldstein will reflect on how #COVID19 impacted advanced therapies and the future implications for #PatientCare.

Advancing Heart Failure Care with LVAD Technology

Dr. Phil Adamson interviews Dr. Douglas Horstmanshof
January 13, 2021

In this episode we discuss the latest in MCS and when advanced therapies should be considered, with Dr. Douglas Horstmanshof, Co-Director, INTEGRIS Advanced Cardiac Care.

Cracking the Case of the HFpEF Patient

Dr. Phil Adamson interviews Dr. Andrew J. Sauer
February 3, 2021

Patients with preserved heart failure are notoriously hard to diagnose and manage. In this episode, Dr. Andrew J. Sauer, Chief of Advanced Heart Failure Therapies Division and Associate Professor at the University of Kansas Health System, will discuss how the use of PA pressure monitoring with the CardioMEMS™ HF System can help optimize GDMT and reduce hospitalizations for this hard to manage patient population.

Between Two Ventricles Teaser

Extraordinary advances during the last few decades have allowed people to not only live longer lives, but fuller ones as well. This, however, has come with its own set of challenges as an aging population experiences a host of medical complications uncommon in younger cohorts; one of which is Heart Failure. To keep pace with its increasing prevalence, HF treatment methodology is continuously being optimized while technological innovations are constantly developed and improved upon, year after year.